Ann: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA, page-4

Safety seems to be alright, no comments on early signals. But that would be too early I guess, especially when just 3 out of planned 20 patients have been dosed with the lowest dose.

And the strange situation continues, CHM is the most advanced CAR-T company listed on the ASX having actually clinical CAR-T trials running and valued ZERO. The other one is IMU and despite cell therapy and CAR-T are the hottest oncology topics in the US with rising valuations of those comps the 2 ones here are getting smashed. The even more strange thing is that those ASX stocks still at pre-clinical are valued 10-15 more than CHM.

3 CAR-Ts, GBM and the above mentioned AML are already poised to be " promoted " to move to rego trials soon and CDH17, the first direct CAR-T taking on solid cancers. And yet, neither the chair nor CHM itself can't find an investor.

Strange indeed or are in-house made mistakes to blame? The science doesn't lie, a screaming buy. From here either total loss or the biggest windfall ever.
Will or can the chair, once called the one with the MIDAS-Touch, turn the fortunes around or will he deliberately drive this gem into the deepest financial ground?


GLTA